Galapagos NV (GLPGF)
USD 26.26
(0.0%)
USD 26.26
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -157.2 Million EUR | 67.67% |
| 2022 | -486.21 Million EUR | 77.96% |
| 2021 | -2.2 Billion EUR | -4.78% |
| 2020 | -2.1 Billion EUR | -14.68% |
| 2019 | -1.83 Billion EUR | -42.26% |
| 2018 | -1.29 Billion EUR | -12.13% |
| 2017 | -1.15 Billion EUR | -18.29% |
| 2016 | -973.17 Million EUR | -186.06% |
| 2015 | -340.19 Million EUR | -81.4% |
| 2014 | -187.54 Million EUR | -32.93% |
| 2013 | -141.08 Million EUR | -49.71% |
| 2012 | -94.24 Million EUR | -197.49% |
| 2011 | -31.67 Million EUR | 19.09% |
| 2010 | -39.15 Million EUR | 14.71% |
| 2009 | -45.9 Million EUR | -79.23% |
| 2008 | -25.61 Million EUR | 42.99% |
| 2007 | -44.92 Million EUR | -2.69% |
| 2006 | -43.75 Million EUR | -85.26% |
| 2005 | -23.61 Million EUR | -129.87% |
| 2004 | -10.27 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -65.39 Million EUR | 58.4% |
| 2024 Q2 | -41.45 Million EUR | 6.02% |
| 2023 Q2 | -82.6 Million EUR | 23.61% |
| 2023 Q4 | -157.2 Million EUR | -8.25% |
| 2023 Q1 | -108.13 Million EUR | 77.76% |
| 2023 Q3 | -145.22 Million EUR | -75.8% |
| 2023 FY | -157.2 Million EUR | 67.67% |
| 2022 Q4 | -486.21 Million EUR | 25.52% |
| 2022 FY | -486.21 Million EUR | 77.96% |
| 2022 Q1 | -1.22 Billion EUR | 44.3% |
| 2022 Q2 | -948.74 Million EUR | 22.8% |
| 2022 Q3 | -652.83 Million EUR | 31.19% |
| 2021 Q3 | -2.8 Billion EUR | -7.39% |
| 2021 FY | -2.2 Billion EUR | -4.78% |
| 2021 Q4 | -2.2 Billion EUR | 21.42% |
| 2021 Q2 | -2.61 Billion EUR | -3.54% |
| 2021 Q1 | -2.52 Billion EUR | -19.92% |
| 2020 FY | -2.1 Billion EUR | -14.68% |
| 2020 Q1 | -2.71 Billion EUR | -48.05% |
| 2020 Q2 | -2.35 Billion EUR | 13.3% |
| 2020 Q3 | -2.05 Billion EUR | 12.65% |
| 2020 Q4 | -2.1 Billion EUR | -2.28% |
| 2019 Q2 | -1.12 Billion EUR | 6.31% |
| 2019 Q3 | -5.57 Billion EUR | -396.73% |
| 2019 Q4 | -1.83 Billion EUR | 67.06% |
| 2019 FY | -1.83 Billion EUR | -42.26% |
| 2019 Q1 | -1.19 Billion EUR | 7.2% |
| 2018 Q2 | -1.06 Billion EUR | 3.74% |
| 2018 Q3 | -1.34 Billion EUR | -25.96% |
| 2018 Q1 | -1.1 Billion EUR | 3.74% |
| 2018 FY | -1.29 Billion EUR | -12.13% |
| 2018 Q4 | -1.29 Billion EUR | 3.93% |
| 2017 Q3 | -1.21 Billion EUR | 3.42% |
| 2017 Q4 | -1.15 Billion EUR | 5.55% |
| 2017 FY | -1.15 Billion EUR | -18.29% |
| 2017 Q1 | -953.33 Million EUR | 2.04% |
| 2017 Q2 | -1.26 Billion EUR | -32.38% |
| 2016 Q3 | -930.73 Million EUR | 3.09% |
| 2016 FY | -973.17 Million EUR | -186.06% |
| 2016 Q4 | -973.17 Million EUR | -4.56% |
| 2016 Q2 | -960.39 Million EUR | 1.82% |
| 2016 Q1 | -978.23 Million EUR | -187.55% |
| 2015 Q4 | -340.19 Million EUR | 7.16% |
| 2015 Q1 | 187.71 Million EUR | 200.09% |
| 2015 FY | -340.19 Million EUR | -81.4% |
| 2015 Q2 | -397.33 Million EUR | -311.67% |
| 2015 Q3 | -366.41 Million EUR | 7.78% |
| 2014 Q4 | -187.54 Million EUR | 0.0% |
| 2014 FY | -187.54 Million EUR | -32.93% |
| 2014 Q1 | -220.66 Million EUR | -56.4% |
| 2014 Q2 | -231.27 Million EUR | -4.81% |
| 2013 Q3 | -138 Million EUR | -1.34% |
| 2013 FY | -141.08 Million EUR | -49.71% |
| 2013 Q2 | -136.18 Million EUR | 0.18% |
| 2013 Q1 | -136.42 Million EUR | -44.76% |
| 2013 Q4 | -141.08 Million EUR | -2.23% |
| 2012 Q4 | -94.24 Million EUR | 0.0% |
| 2012 FY | -94.24 Million EUR | -197.49% |
| 2012 Q2 | -121.93 Million EUR | 0.0% |
| 2011 Q4 | -31.67 Million EUR | 0.0% |
| 2011 Q2 | -48.68 Million EUR | 0.0% |
| 2011 FY | -31.67 Million EUR | 19.09% |
| 2010 Q4 | -39.15 Million EUR | 0.0% |
| 2010 Q2 | -25.89 Million EUR | 0.0% |
| 2010 FY | -39.15 Million EUR | 14.71% |
| 2009 Q2 | -16.99 Million EUR | 0.0% |
| 2009 FY | -45.9 Million EUR | -79.23% |
| 2009 Q4 | -45.9 Million EUR | 0.0% |
| 2008 Q4 | -25.61 Million EUR | 0.0% |
| 2008 FY | -25.61 Million EUR | 42.99% |
| 2007 FY | -44.92 Million EUR | -2.69% |
| 2006 FY | -43.75 Million EUR | -85.26% |
| 2005 FY | -23.61 Million EUR | -129.87% |
| 2004 FY | -10.27 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 1097.317% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 3917.535% |
| SQZ Biotechnologies Company | -36.23 Million USD | -333.818% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 467.366% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -2393.559% |
| Mesoblast Limited | 55.85 Million USD | 381.439% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 17055.282% |
| Genus plc | 190.6 Million USD | 182.48% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 7131.253% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 13050.701% |
| Marizyme, Inc. | 18.56 Million USD | 946.609% |
| ContraFect Corporation | -6.02 Million USD | -2508.812% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 23218.676% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 116861.859% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 13705.942% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 7111.18% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 2957.324% |
| MultiCell Technologies, Inc. | 90.04 USD | 174596945.846% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -21318.489% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 1314.329% |
| EV Biologics, Inc. | 1.36 Million USD | 11591.983% |
| Q BioMed Inc. | 4.06 Million USD | 3972.086% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 614.522% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 25359.655% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 15700.328% |
| Biomind Labs Inc. | 711.4 Thousand USD | 22198.195% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 243.171% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 1327.548% |
| Skye Bioscience, Inc. | -5.72 Million USD | -2647.707% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 18374.763% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 112548.142% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 2883.228% |
| IMV Inc. | 7.67 Million USD | 2149.496% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 791397.126% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 7239.344% |
| GB Sciences, Inc. | 1.74 Million USD | 9097.056% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -85437.141% |
| HST Global, Inc. | 96.79 Thousand USD | 162515.671% |
| CSL Limited | 10.52 Billion USD | 101.494% |
| Halberd Corporation | 144.72 Thousand USD | 108727.635% |
| Enzolytics Inc. | 981.65 Thousand USD | 16114.469% |
| Resverlogix Corp. | 6.45 Million USD | 2536.94% |
| Affymax, Inc. | -5.59 Million USD | -2708.773% |
| SYBLEU INC | 473.71 Thousand USD | 33286.057% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -23256.049% |
| argenx SE | -2.02 Billion USD | 92.251% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 461.945% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -234.398% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 5903.963% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -1678.377% |
| AVAX Technologies, Inc. | -5.9 Million USD | -2563.078% |
| Zenith Capital Corp. | 10.06 Thousand USD | 1562172.734% |
| Genscript Biotech Corporation | -1.06 Billion USD | 85.188% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 78534.082% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 6688.632% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 95661.337% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 359.65% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 7962.74% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | -6016.928% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 43803.817% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 875.335% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -858110.503% |
| BioStem Technologies, Inc. | 4.47 Million USD | 3615.354% |
| ONE Bio Corp. | 9.04 Million USD | 1839.009% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 78213.727% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -12000434.351% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 76333.773% |
| Agentix Corp. | 37.63 Thousand USD | 417859.294% |
| LadRx Corporation | -2.03 Million USD | -7619.587% |
| Cell Source, Inc. | 9.23 Million USD | 1802.854% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -770220.463% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 24850.499% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 24850.499% |
| NovAccess Global Inc. | 2.17 Million USD | 7316.412% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 2323.273% |
| Itoco Inc. | 228.3 Thousand USD | 68958.325% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 115702.733% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 3271.414% |
| Kadimastem Ltd | -253.1 Thousand USD | -62012.113% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 39220.914% |
| CytoDyn Inc. | 20.26 Million USD | 875.871% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -24297736.167% |
| Mobile Lads Corp. | 484.23 Thousand USD | 32565.223% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -1696072.13% |
| Qrons Inc. | 351.42 Thousand USD | 44833.899% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 2140.059% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -62878.527% |
| Rebus Holdings, Inc. | 305 Thousand USD | 51643.279% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 3627.176% |
| International Stem Cell Corporation | 2.59 Million USD | 6169.768% |
| Bioxytran, Inc. | 1.89 Million USD | 8378.785% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 251981.819% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 7308.354% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 4677.956% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 1938.033% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 20447.602% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -12476.56% |
| Neutra Corp. | 52.18 Thousand USD | 301337.856% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -6216.071% |
| PureTech Health plc | -167.19 Million USD | 5.975% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -64090.227% |
| IXICO plc | -4.44 Million USD | -3437.044% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 1289.25% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 386.607% |
| CSL Limited | 10.52 Billion USD | 101.494% |
| Cellectis S.A. | -43.81 Million USD | -258.766% |